Literature DB >> 21054775

Are the recommended blood pressure goals in high-risk patients based on outcome data or opinion?

Debbie L Cohen1, Raymond R Townsend.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21054775      PMCID： PMC8108771          DOI： 10.1111/j.1751-7176.2010.00361.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  11 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

2.  Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention.

Authors:  Clive Rosendorff; Henry R Black; Christopher P Cannon; Bernard J Gersh; Joel Gore; Joseph L Izzo; Norman M Kaplan; Christopher M O'Connor; Patrick T O'Gara; Suzanne Oparil
Journal:  Circulation       Date:  2007-05-14       Impact factor: 29.690

3.  Effects of intensive blood-pressure control in type 2 diabetes mellitus.

Authors:  William C Cushman; Gregory W Evans; Robert P Byington; David C Goff; Richard H Grimm; Jeffrey A Cutler; Denise G Simons-Morton; Jan N Basile; Marshall A Corson; Jeffrey L Probstfield; Lois Katz; Kevin A Peterson; William T Friedewald; John B Buse; J Thomas Bigger; Hertzel C Gerstein; Faramarz Ismail-Beigi
Journal:  N Engl J Med       Date:  2010-03-14       Impact factor: 91.245

4.  Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial.

Authors:  Steven E Nissen; E Murat Tuzcu; Peter Libby; Paul D Thompson; Magdi Ghali; Dahlia Garza; Lance Berman; Harry Shi; Ethel Buebendorf; Eric J Topol
Journal:  JAMA       Date:  2004-11-10       Impact factor: 56.272

5.  Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial.

Authors:  Philip A Poole-Wilson; Jacobus Lubsen; Bridget-Anne Kirwan; Fred J van Dalen; Gilbert Wagener; Nicolas Danchin; Hanjörg Just; Keith A A Fox; Stuart J Pocock; Tim C Clayton; Michael Motro; John D Parker; Martial G Bourassa; Anthony M Dart; Per Hildebrandt; Ake Hjalmarson; Johannes A Kragten; G Peter Molhoek; Jan-Erik Otterstad; Ricardo Seabra-Gomes; Jordi Soler-Soler; Simon Weber
Journal:  Lancet       Date:  2004 Sep 4-10       Impact factor: 79.321

6.  The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  JAMA       Date:  2003-05-14       Impact factor: 56.272

7.  Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).

Authors:  K M Fox
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

8.  KDOQI hypertension, dyslipidemia, and diabetes care guidelines and current care patterns in the United States CKD population: National Health and Nutrition Examination Survey 1999-2004.

Authors:  Jon J Snyder; Allan J Collins
Journal:  Am J Nephrol       Date:  2009-02-06       Impact factor: 3.754

Review 9.  Treatment blood pressure targets for hypertension.

Authors:  Jose Agustin Arguedas; Marco I Perez; James M Wright
Journal:  Cochrane Database Syst Rev       Date:  2009-07-08

10.  Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk patients intolerant to angiotensin-converting enzyme inhibitors: a randomised controlled trial.

Authors:  S Yusuf; K Teo; C Anderson; J Pogue; L Dyal; I Copland; H Schumacher; G Dagenais; P Sleight
Journal:  Lancet       Date:  2008-08-29       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.